Log In
BCIQ
Print this Print this
 

AG014

  Manage Alerts
Collapse Summary General Information
Company Intrexon Corp.
DescriptionLactococcus lactis ActoBiotic genetically modified to express and secrete an anti-tumor necrosis factor (TNF) alpha antibody
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionCell therapy; Antibody
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPhase I
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat inflammatory bowel disease (IBD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$60.0M

$30.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/24/2015

$60.0M

$30.0M

0

Get a free BioCentury trial today